Relatlimab

A4DAB222 | Cancer | Approved

Target LAG3/CD223

Isotype / Subclass G4 / IgG4

Company

Bristol-Myers Squibb Ono Pharmaceutical Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Clinical Status Approved

Format Whole mAb

Synonyms

BMS 986016 ONO-4482 BMS986016 BMS 986016 ONO 4482 ONO4482

pH Formulation —

IMGT PubChem (336446922) PubChem (374363887) PubChem (381127923) PubChem (404772299) PubChem (472419200) PubChem (472435497) PubChem (472439867) PubChem (488418527) PubChem (498151132) PubChem (505875146) Thera-SAbDab YAbS

Avg A4D Score

-0.6896

Score Range

-0.69 to -0.69

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB222_7um3_I_M	7um3	99%	-0.6883	6.5	4.0	-0.3144	-0.7323
A4DAB222_7um3_H_L	7um3	99%	-0.691	6.5	4.0	-0.3085	-0.7361

Relatlimab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2